Ornithine transcarbamylase deficiency (OTCD) is considered to be the most common disorder of the urea cycle [1] [2] [3] [4]. Having in mind the X-linked pattern of inheritance, this condition is principally diagnosed in males, although female cases have been described in the literature [5] [6]. Signs and symptoms stem from the inability of the body to form urea from ammonia and other compounds due to deficiency of ornithine transcarbamylase (OTC), a key enzyme in the urea cycle [5] [6]. As a result, hyperammonemia of variable severity is the principal pathological feature of OTCD [4] [7]. Depending on the type of mutation, OTCD manifests in two age groups, although signs and symptoms may manifest at any point during life [1]. The worst affected patients are hemizygous males, in whom a neonatal onset of hyperammonemia is manifested by poor feeding, vomiting, lethargy, tachypnea, and irritability [3] [6]. In infants and younger children, intellectual and behavioral deficits are frequent [4] [8]. A neonatal onset almost always implies that more severe manifestations will appear and a poorer prognosis is expected, as hemizygous males and individuals harboring null alleles (suggesting a complete absence of enzyme activity) develop seizures, respiratory failure, encephalopathy and coma, which is life-threatening [3] [5] [6] [7]. Conversely, a much milder clinical presentation is seen in heterozygote females and males with incomplete OTCD, since only partial enzyme deficiency occurs [5]. High protein meals, fasting, severe infections, pregnancy, high-dose corticosteroids, use of sodium valproate, various invasive medical procedures or chemotherapy can induce hyperammonemia [3] [4] [6]. Additional reports suggest that a voluntary adoption of a vegetarian diet could be an important clue as well [5].

The workup of neonates or adults in whom OTCD, or any UCD in general, is suspected, should start with a meticulous patient history that will determine similar manifestations or neonatal deaths in the family, voluntary avoidance of protein intake in diet, and either neurological or psychiatric disorders in close family members that cold be attributed to OTCD [2]. A thorough physical examination must follow, comprised of a full body inspection and a complete neurological exam that will assess various CNS abnormalities and the state of consciousness. Apart from serum measurement of ammonia levels, which is the first important marker when a disorder of the urea cycle is suspected, an extensive laboratory workup should be carried out soon after, comprised of liver and kidney function tests, arterial blood gas analysis (ABG), a complete blood count (CBC) and a full electrolyte panel. OTCD-specific studies include detection of plasma citrulline and arginine, and most importantly, evaluation of orotic acid in urine [2] [3]. The urinary increase of orotic acid, together with low plasma citrulline and arginine, is a diagnostic hallmark of hyperammonemia due to OTCD [2], in which case genetic studies are employed for confirmation. Mutational analysis is performed to detect mutations responsible for OTCD, located on the p21.1 segment of chromosome X [1] [5] [6]. If UCDs are confirmed in parents or close family members, a prenatal diagnosis can be achieved through chorionic villus sampling (CVS) [5].

The primary goal of treatment for OTC deficiency is to reduce ammonia levels in the blood. This can be achieved through dietary management, medications, and in some cases, liver transplantation. A low-protein diet helps minimize ammonia production, while medications such as sodium phenylbutyrate or sodium benzoate can help remove excess ammonia. In severe cases, dialysis may be necessary to rapidly reduce ammonia levels. Liver transplantation can provide a long-term solution by restoring normal enzyme function.

The prognosis for individuals with OTC deficiency varies widely depending on the severity of the condition and the effectiveness of treatment. Early diagnosis and management are crucial for preventing serious complications. With appropriate treatment, many individuals can lead relatively normal lives, although they may need to adhere to dietary restrictions and medication regimens. In severe cases, especially if untreated, the condition can lead to significant neurological damage or be life-threatening.

OTC deficiency is caused by mutations in the OTC gene, which provides instructions for making the enzyme ornithine transcarbamylase. This enzyme is essential for the urea cycle, which converts ammonia into urea for excretion. The disorder is inherited in an X-linked manner, meaning the gene is located on the X chromosome. Males, who have only one X chromosome, are typically more severely affected, while females, with two X chromosomes, may have milder symptoms or be carriers.

OTC deficiency is the most common urea cycle disorder, but it is still considered rare, affecting approximately 1 in 14,000 to 1 in 80,000 people. The condition is more frequently diagnosed in males due to the X-linked pattern of inheritance. However, females can also be affected, particularly if they inherit a mutated gene from both parents or experience skewed X-chromosome inactivation.

In OTC deficiency, the lack of functional ornithine transcarbamylase disrupts the urea cycle, leading to the accumulation of ammonia and other toxic substances in the blood. Ammonia is particularly harmful to the brain, causing neurological symptoms and damage. The buildup of orotic acid in the urine is a hallmark of the disorder, resulting from the diversion of carbamoyl phosphate, a urea cycle intermediate, into an alternative metabolic pathway.

Currently, there is no way to prevent OTC deficiency, as it is a genetic condition. However, genetic counseling can help at-risk families understand their chances of having a child with the disorder. Prenatal testing and carrier screening are available for families with a known history of OTC deficiency, allowing for early diagnosis and intervention.

Ornithine Transcarbamylase Deficiency is a genetic disorder that disrupts the urea cycle, leading to toxic ammonia buildup in the blood. Symptoms can range from mild to severe and may appear at any age. Diagnosis involves blood and urine tests, along with genetic analysis. Treatment focuses on reducing ammonia levels through dietary management, medications, and potentially liver transplantation. Early diagnosis and intervention are key to improving outcomes.

If you or a loved one has been diagnosed with OTC deficiency, it's important to work closely with a healthcare team to manage the condition. This may involve regular monitoring of ammonia levels, adhering to a low-protein diet, and taking prescribed medications. Understanding the genetic nature of the disorder can help in planning for the future, including family planning and genetic counseling. With proper management, many individuals with OTC deficiency can lead healthy, fulfilling lives.

1. Batshaw ML, Tuchman M, Summar M, Seminara J, the Members of the Urea Cycle Disorders Consortium. A longitudinal study of urea cycle disorders. Molecular genetics and metabolism. 2014;113(0):127-130.
2. Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
3. Pinner JR, Freckmann M-L, Kirk EP, Yoshino M. Female heterozygotes for the hypomorphic R40H mutation can have ornithine transcarbamylase deficiency and present in early adolescence: a case report and review of the literature. Journal of Medical Case Reports. 2010;4:361.
4. Ben-Ari Z, Dalal A, Morry A, et al. Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet. J Hepatol. 2010;52(2):292-295.
5. Gordon N. Ornithine transcarbamylase deficiency: a urea cycle defect. Eur J Paediatr Neurol. 2003;7(3):115-121.
6. Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype–Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. J Genet Genomics. 2015;42(5):181-194.
7. Venkateswaran L, Scaglia F, McLin V, et al. Ornithine Transcarbamylase Deficiency: A Possible Risk Factor for Thrombosis. Pediatr Blood Cancer. 2009;53(1):100-102.
8. Krivitzky L, Babikian T, Lee H, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, Adaptive, and Behavioral Functioning in Children with Urea Cycle Disorders. Pediatr Res. 2009;66(1):96-101.